TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10566321

Group type: EXPERIMENTAL
Intervention: Automated Term Dissection (ATD)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Human Term Dissection (HTD)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 500
Study: 8739489

Group type: EXPERIMENTAL
Intervention: Continuous SCMC‐Lys 2.7 g once daily
Number of subjects: 662

Group type: COMPARATOR
Intervention: Intermittent SCMC‐Lys 2.7 g
Number of subjects: 662

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 662
Study: 1721550

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6797571

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg by mouth twice daily
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide 250 mg by mouth four times daily with hydrocortisone 20 mg twice daily
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide after tamoxifen failure
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Tamoxifen after aminoglutethimide failure
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Side effects of aminoglutethimide
Number of subjects: 117

Group type: COMPARATOR
Intervention: Side effects of tamoxifen
Number of subjects: 117
Study: 31000253

Group type: EXPERIMENTAL
Intervention: Factors influencing live fish consumption frequency
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Price importance
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Safety satisfaction
Number of subjects: 800
Study: 28424258

Group type: EXPERIMENTAL
Intervention: Hepcidin concentrations measured at 14, 20, and 30 weeks of gestation
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Hepcidin as a diagnostic test for iron deficiency
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Hemoglobin levels measured at 14, 20, and 30 weeks of gestation
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Ferritin levels measured at 14, 20, and 30 weeks of gestation
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: sTfR levels measured at 14, 20, and 30 weeks of gestation
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels measured at 14, 20, and 30 weeks of gestation
Number of subjects: 395
Study: 25876654

Group type: EXPERIMENTAL
Intervention: Duty cycle 0.6
Number of subjects: 9

Group type: COMPARATOR
Intervention: Duty cycle 0.3
Number of subjects: 9
Study: 24229349

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts (in participants with DM2)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 224
Study: 21324611

Group type: EXPERIMENTAL
Intervention: Craving
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Attention disturbance
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Restlessness
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Arousal
Number of subjects: 351
Study: 19551667

Group type: EXPERIMENTAL
Intervention: Wavefront-guided customized PRK
Number of subjects: 56

Group type: COMPARATOR
Intervention: Custom-Q ablation
Number of subjects: 56
Study: 16899123

Group type: EXPERIMENTAL
Intervention: Tonsillectomy and adeno-tonsillectomy
Number of subjects: 406

Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 406
Study: 14700552

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 12 months
Number of subjects: 19

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 19
Study: 11299099

Group type: EXPERIMENTAL
Intervention: Semi-quantitative food frequency questionnaire (FFQ) administered at baseline (FFQ1) and repeated 1 year later (FFQ2)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Semi-quantitative food frequency questionnaire (FFQ2) compared to 1-week diet records (DRs)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Diet records (DR) compared to FFQ2
Number of subjects: 83
Study: 9402445

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment in high compliance group (compliance > or = 75%)
Number of subjects: 0
Study: 8291123

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzodiazepine with Flumazenil
Number of subjects: 0
Study: 3625582

Group type: EXPERIMENTAL
Intervention: Positive self-verbalizations (PSV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Negative self-verbalizations (NSV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of positive and negative self-verbalizations (PSV + NSV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Test-retest control group
Number of subjects: 60
Study: 31512157

Group type: EXPERIMENTAL
Intervention: Pilates
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 29478012

Group type: EXPERIMENTAL
Intervention: Intervention group (IG): Checklist-based interview conducted by healthcare assistant, medication reconciliation, optimisation by general practitioner with decision support system.
Number of subjects: 505

Group type: COMPARATOR
Intervention: Control group (CG): Usual care.
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Intervention group (IG): Quality of life assessment.
Number of subjects: 505

Group type: COMPARATOR
Intervention: Control group (CG): Quality of life assessment.
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Intervention group (IG): Functioning assessment.
Number of subjects: 505

Group type: COMPARATOR
Intervention: Control group (CG): Functioning assessment.
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Intervention group (IG): Medication adherence assessment.
Number of subjects: 505

Group type: COMPARATOR
Intervention: Control group (CG): Medication adherence assessment.
Number of subjects: 505
Study: 27403743

Group type: EXPERIMENTAL
Intervention: Monthly bee venom injections (100 μg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline injections)
Number of subjects: 40
Study: 24567394

Group type: EXPERIMENTAL
Intervention: Repeated intergroup contact with Spanish-speaking confederates inserted into daily routines for a period of days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 0
Study: 22444791

Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 582

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 582
Study: 20100234

Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 94
Study: 17335594

Group type: EXPERIMENTAL
Intervention: Noncatheterized group (n = 28)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Catheterized group (n = 27)
Number of subjects: 55
Study: 15025402

Group type: EXPERIMENTAL
Intervention: Epinephrine (adrenaline) for out-of-hospital treatment of anaphylaxis; specific dosage not mentioned, but references to EpiPen Jr 0.15 mg and EpiPen 0.3 mg as available auto-injectors.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epinephrine administration methods; subcutaneous injection or inhalation from a pressurized metered-dose inhaler instead of intramuscular injection.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed-dose formulations of epinephrine; specific formulations not mentioned.
Number of subjects: 0
Study: 11340417

Group type: EXPERIMENTAL
Intervention: eFR (5-min verbal standard instruction in elementary exercises of FR)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: IT (inhalative terbutaline)
Number of subjects: 21

Group type: COMPARATOR
Intervention: PRT (placebo relaxation technique)
Number of subjects: 21
Study: 9100428

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.8 mg/kg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg and 0.8 mg/kg
Number of subjects: 23
Study: 7959501

Group type: EXPERIMENTAL
Intervention: 600 mg magnesium/day in the form of trimagnesium dieitrate
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 43
Study: 3296735

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 375 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 120 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (both doses)
Number of subjects: 68
Study: 31667542

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model for estimating stone passage rate
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard statistical tests
Number of subjects: 192
Study: 29141727

Group type: EXPERIMENTAL
Intervention: Point-of-Care Ultrasound (POCUS)
Number of subjects: 425
Study: 27514348

Group type: EXPERIMENTAL
Intervention: E-learning resource access
Number of subjects: 32

Group type: COMPARATOR
Intervention: No e-learning resource access (Control)
Number of subjects: 32
Study: 24487458

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 200 mcg 10 min prior to tracheal intubation and 6 and 24 h after extubation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 200 mcg 6 and 24 h after extubation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 120
Study: 23457130

Group type: EXPERIMENTAL
Intervention: 5 mg/Kg of tranexamic acid (TA)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 15 mg/Kg of tranexamic acid (TA)
Number of subjects: 70
Study: 20522472

Group type: EXPERIMENTAL
Intervention: Pre-measured sachets
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Weighing
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Scoops
Number of subjects: 47
Study: 18482376

Group type: EXPERIMENTAL
Intervention: Hard sole group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Soft sole group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 15870666

Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment (2.0 to 0.75 mg/kg per day for 10 days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 15307697

Group type: EXPERIMENTAL
Intervention: Chuanfuling (CFL) sticking
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pulmicort inhalation (WM)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 90
Study: 11606149

Group type: EXPERIMENTAL
Intervention: Enalapril maleate, candesartan cilexetil, or both for 17 weeks followed by metoprolol succinate or placebo for 26 weeks
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Study medications (Enalapril maleate, candesartan cilexetil, metoprolol succinate)
Number of subjects: 768

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768
Study: 9204652

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg daily for 90 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 7952252

Group type: EXPERIMENTAL
Intervention: First-voided urine specimens
Number of subjects: 489

Group type: COMPARATOR
Intervention: Endocervical swab specimens
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Combination of urine and endocervical swab specimens
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Testing for low levels of chlamydial antigen
Number of subjects: 489
Study: 3118349

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30466429

Group type: EXPERIMENTAL
Intervention: Somatic Experiencing (SE) + Physiotherapy (PT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Physiotherapy (PT) alone
Number of subjects: 140
Study: 28087555

Group type: EXPERIMENTAL
Intervention: Reallocation of prolonged sitting to standing
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Reallocation to stepping
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Reallocation of short sitting time to stepping
Number of subjects: 435
Study: 22996027

Group type: EXPERIMENTAL
Intervention: Uphill interval training (G(Hill) = 12)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Level-grade interval training (G(Flat) = 12)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (G(Con) = 8)
Number of subjects: 32
Study: 21107951

Group type: EXPERIMENTAL
Intervention: Ozone therapy (30 mg/ml mixture of oxygen and ozone, 1-7 ml intradiscal and 3 ml periganglionic)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Physiatric and kinetic treatment (magnetotherapy)
Number of subjects: 270
Study: 18272916

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by goserelin
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by tamoxifen
Number of subjects: 1631

Group type: COMPARATOR
Intervention: Chemo-endocrine therapy
Number of subjects: 1631

Group type: COMPARATOR
Intervention: Endocrine therapy (tamoxifen alone)
Number of subjects: 1631
Study: 16940192

Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (5-MTHF) intravenous infusion
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (5-MTHF) ex vivo incubation (1 to 100 micromol/L)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 12657408

Group type: EXPERIMENTAL
Intervention: ECT administered soon (<210 sec) after anesthetic induction
Number of subjects: 9

Group type: COMPARATOR
Intervention: ECT administered later (between 210 sec and 360 sec) after anesthetic induction
Number of subjects: 9
Study: 10933121

Group type: COMPARATOR
Intervention: d-amphetamine (placebo-controlled)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Efamol (evening primrose oil, rich in gamma-linolenic acid) (placebo-controlled)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both treatments (d-amphetamine and Efamol)
Number of subjects: 18
Study: 9179214

Group type: EXPERIMENTAL
Intervention: Tl-201
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sestamibi Tc 99m
Number of subjects: 160
Study: 1542853

Group type: EXPERIMENTAL
Intervention: Cell Saver (CS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hemofiltration (HF)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acute Normovolemic Hemodilution (ANH) with CS (ANH-CS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ANH with HF (ANH-HF)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acute Plasmapheresis (APP) with CS (APP-CS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: APP with HF (APP-HF)
Number of subjects: 90
Study: 3924814

Group type: EXPERIMENTAL
Intervention: Augmentin (amoxycillin 3 g and potassium clavulanate 125 mg)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Amoxycillin 3 g with probenecid 1 g by mouth
Number of subjects: 220
Study: 30673744

Group type: EXPERIMENTAL
Intervention: Antiretroviral care delivery designed to address barriers to HIV care, including decreased clinic visit frequency and flexible, patient-centered care with retention support.
Number of subjects: 1863

Group type: EXPERIMENTAL
Intervention: Antiretroviral care delivery designed to address barriers to HIV care.
Number of subjects: 1863
Study: 28533402

Group type: EXPERIMENTAL
Intervention: LPS-injected (sick)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline-injected (healthy)
Number of subjects: 22
Study: 25189856

Group type: EXPERIMENTAL
Intervention: Low dose of alcohol (0.45 g/kg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 23432189

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil
Number of subjects: 7447

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with mixed nuts
Number of subjects: 7447

Group type: COMPARATOR
Intervention: Control diet (advice to reduce dietary fat)
Number of subjects: 7447
Study: 21135532

Group type: EXPERIMENTAL
Intervention: Rowatinex® (special terpene combination; 3 × 2 capsules/day)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 19076984

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Domperidone
Number of subjects: 0
Study: 17229225

Group type: EXPERIMENTAL
Intervention: Omeprazole magnesium 20.6 mg o.m. (Ome-Mg 20)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Famotidine 10 mg b.d. (Fam 10)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Famotidine 20 mg b.d. (Fam 20)
Number of subjects: 31
Study: 15029940

Group type: EXPERIMENTAL
Intervention: Brace with minimal tension
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Brace with 25‐N tension
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Brace with 50‐N tension
Number of subjects: 15

Group type: COMPARATOR
Intervention: No brace
Number of subjects: 15
Study: 11677969

Group type: EXPERIMENTAL
Intervention: Submucosal epinephrine injection (1:10,000) before polypectomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: No injection (control group) before polypectomy
Number of subjects: 120
Study: 9476184

Group type: COMPARATOR
Intervention: Intravenous L-arginine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Chronic oral intake of L-arginine
Number of subjects: 8
Study: 7946898

Group type: EXPERIMENTAL
Intervention: Sodium selenite 200 micrograms/d for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro supplementation with 1 x 10(‐7) M Se (as sodium selenite)
Number of subjects: 0
Study: 2892807

Group type: EXPERIMENTAL
Intervention: Ro 16-8714 (5 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ro 16-8714 (10 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ro 16-8714 (20 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31163053

Group type: EXPERIMENTAL
Intervention: Assessment of past week alcohol consumption prior to the AUDIT-C screening
Number of subjects: 2379

Group type: COMPARATOR
Intervention: AUDIT-C screening after past week alcohol consumption assessment
Number of subjects: 2379
Study: 28461224

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5887
Study: 25017108

Group type: EXPERIMENTAL
Intervention: Continuous nasal prongs
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Continuous nasal mask
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Alternating mask/prongs
Number of subjects: 78
Study: 23559149

Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus standard weekly cetuximab (arm 1)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus cetuximab (500 mg/m(2)) every second week (arm 2)
Number of subjects: 152
Study: 21752025

Group type: EXPERIMENTAL
Intervention: Two-sided messages
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: High-NFC individuals
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Moderate time pressure
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Two-sided messages under low or moderate time pressure for high-NFC individuals
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: One-sided messages under low or high time pressure for low-NFC individuals
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Two-sided messages under moderate time pressure for low-NFC individuals
Number of subjects: 336
Study: 19259629

Group type: EXPERIMENTAL
Intervention: 303 Algorithm
Number of subjects: 193

Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 193
Study: 16765862

Group type: EXPERIMENTAL
Intervention: Clinical pathway for treating pneumonia in nursing homes; Details: Not specified
Number of subjects: 7
Study: 14675411

Group type: EXPERIMENTAL
Intervention: Aspirin (75-250 mg/d)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (untreated subjects)
Number of subjects: 55
Study: 14579019

Group type: EXPERIMENTAL
Intervention: Minimally invasive percutaneous epidural neurolysis according to Racz's technique
Number of subjects: 25
Study: 10467476

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% (n = 10)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (n = 10)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (n = 9)
Number of subjects: 29
Study: 8849189

Group type: EXPERIMENTAL
Intervention: Immune and scarification Bacillus Calmette-Guerin (BCG)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 43
Study: 2142225

Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis
Number of subjects: 25
Study: 649865

Group type: EXPERIMENTAL
Intervention: Marihuana with no motivation instructions
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Marihuana with 'try as hard as possible' instructions
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Marihuana with small monetary incentive
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Marihuana with substantial monetary incentive
Number of subjects: 112

Group type: COMPARATOR
Intervention: No drug with no motivation instructions
Number of subjects: 112

Group type: COMPARATOR
Intervention: No drug with 'try as hard as possible' instructions
Number of subjects: 112

Group type: COMPARATOR
Intervention: No drug with small monetary incentive
Number of subjects: 112

Group type: COMPARATOR
Intervention: No drug with substantial monetary incentive
Number of subjects: 112
Study: 31616939

Group type: EXPERIMENTAL
Intervention: Cousers of cannabis and tobacco
Number of subjects: 1078
Study: 30958544

Group type: EXPERIMENTAL
Intervention: Exenatide 5µg twice daily for 2 weeks, then 10µg twice daily for 4 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 10
Study: 28603135

Group type: EXPERIMENTAL
Intervention: Clopidogrel combined with pantoprazole treatment
Number of subjects: 478

Group type: COMPARATOR
Intervention: Clopidogrel treatment alone (Control)
Number of subjects: 478
Study: 27107896

Group type: EXPERIMENTAL
Intervention: Real-time kinematic biofeedback
Number of subjects: 30
Study: 25141114

Group type: EXPERIMENTAL
Intervention: Bio-Manguinhos epoetin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Biosimilar epoetin
Number of subjects: 74
Study: 23095282

Group type: EXPERIMENTAL
Intervention: Anti-tumor necrosis factor-α therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Stable cardiovascular disease (control group)
Number of subjects: 17
Study: 19631849

Group type: EXPERIMENTAL
Intervention: Various treatments for periodontal diseases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coordinated treatment of periodontic and endodontic diseases
Number of subjects: 0